![](http://investorshub.advfn.com/images/default_ih_profile2_4848.jpg?cb=0)
Thursday, November 21, 2013 7:38:39 PM
The following is from FDA's "Father of GLP":
GLP is a regulation. It is not only good analytical practice. Good analytical practice is important, but it is not enough. For example, the laboratory must have a specific organizational structure and procedures to perform and document laboratory work. The objective is not only quality of data but also traceability and integrity of data. But the biggest difference between GLP and Non-GLP work is the type and amount of documentation.
For a GLP inspector it should be possible to look at the documentation and to easily find out
who has done a study,
how the experiment was carried out,-
which procedures have been used, and
whether there has been any problem and if so
how it has been solved.
And this should not only be possible during and right after the study has been finished but also 5 to 10 or more years later. ~ Father of GLP
http://www.labcompliance.com/tutorial/glp/
Monday's PR was just to let us know that NanoViricides, Inc. is moving along on projects/activities already known to us, on-track in a timeline.
What are we waiting for? The detailed report from KARD Scientific Boston that confirms "NanoViricides, Inc. (NNVC.PK) Says Early Results Indicate that FluCide® Was Extremely Safe in a Non-GLP Small Animal Tox Study" and indicates we are ready to move forward with the FluCide candidate GLP "tox studies". FluCide was also found to be "well tolerated". Nevertheless, as robi-1-kenobi stated on earlier post(s), we should move up huge. I am looking forward to 10-25% daily for 3 to 4 consecutive days, climbs that will take NNVC beyond 7.59 pps on 260K+ daily volume. You?
Recent NNVC News
- NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • InvestorsHub NewsWire • 05/02/2024 02:07:42 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/16/2024 09:53:32 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 02/14/2024 09:55:35 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/19/2024 09:44:48 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 12/04/2023 09:08:49 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 10/13/2023 08:30:41 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 09/28/2023 08:44:54 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/01/2023 08:46:45 PM
FEATURED ELEMENT79 GOLD CORP PROVIDES UPDATE ON CHACHAS COMMUNITY CHARTER AND REVENUE GENERATION, M&A ACTIVITIES • Jul 30, 2024 8:00 AM
Avant Technologies Opens Equity Line with GHS Investments as Company Explores Expansion into Additional Technologies • AVAI • Jul 30, 2024 8:00 AM
INDEXR AI Merges With Moon Equity Holdings Corp. (MONI), Creating a Leading-edge Technology Company • MONI • Jul 29, 2024 9:59 AM
Cannabix Technologies to Deliver Innovative Breath Logix Alcohol Screening Device to Texas, USA • BLOZF • Jul 29, 2024 9:07 AM
BNCM AND DELEX UNVEIL POST-MERGER MANAGEMENT PLANS • BNCM • Jul 29, 2024 9:00 AM
Glidelogic Corp. Announces Revolutionary AI-Generated Content Copyright Protection Solution • GDLG • Jul 26, 2024 12:30 PM